AUTHOR=Li Ke , Zhu Yan , Cheng Jiawei , Li Anlei , Liu Yuxing , Yang Xinyi , Huang Hao , Peng Zhangzhe , Xu Hui 

TITLE=A novel lipid metabolism gene signature for clear cell renal cell carcinoma using integrated bioinformatics analysis

JOURNAL=Frontiers in Cell and Developmental Biology

VOLUME=11

YEAR=2023

URL=https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2023.1078759

DOI=10.3389/fcell.2023.1078759

ISSN=2296-634X

ABSTRACT=<p><bold>Background:</bold> Clear cell renal cell carcinoma (ccRCC), which is the most prevalent type of renal cell carcinoma, has a high mortality rate. Lipid metabolism reprogramming is a hallmark of ccRCC progression, but its specific mechanism remains unclear. Here, the relationship between dysregulated lipid metabolism genes (LMGs) and ccRCC progression was investigated.</p><p><bold>Methods:</bold> The ccRCC transcriptome data and patients’ clinical traits were obtained from several databases. A list of LMGs was selected, differentially expressed gene screening performed to detect differential LMGs, survival analysis performed, a prognostic model established, and immune landscape evaluated using the CIBERSORT algorithm. Gene Set Variation Analysis and Gene set enrichment analysis were conducted to explore the mechanism by which LMGs affect ccRCC progression. Single-cell RNA-sequencing data were obtained from relevant datasets. Immunohistochemistry and RT-PCR were used to validate the expression of prognostic LMGs.</p><p><bold>Results:</bold> Seventy-one differential LMGs were identified between ccRCC and control samples, and a novel risk score model established comprising 11 LMGs (<italic>ABCB4</italic>, <italic>DPEP1</italic>, <italic>IL4I1</italic>, <italic>ENO2</italic>, <italic>PLD4</italic>, <italic>CEL</italic>, <italic>HSD11B2</italic>, <italic>ACADSB</italic>, <italic>ELOVL2</italic>, <italic>LPA</italic>, and <italic>PIK3R6</italic>); this risk model could predict ccRCC survival. The high-risk group had worse prognoses and higher immune pathway activation and cancer development.</p><p><bold>Conclusion:</bold> Our results showed that this prognostic model can affect ccRCC progression.</p>